Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

In Vivo Engineering of Virus-Specific T Cells for CAR T Cell Therapy Against Multiple Myeloma

Award Number: R01CA304559
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2026
PERIOD OF PERFORMANCE END DATE: 05/31/2031

Group Awards By:

View Award Description

In Vivo Engineering of Virus-Specific T Cells for CAR T Cell Therapy Against Multiple Myeloma - PROJECT SUMMARY The clinical benefit of CAR T cells that target B Cell Maturation Antigen (BCMA) for multiple myeloma (MM) patients has led to landmark regulatory approvals since 2021. Yet clinical application of CAR T cells in MM has been hampered by prohibitive costs and manufacturing issues including lengthy vein-to-vein time, severely limiting patient access. While ‘off-the-shelf’ BCMA-directed CD3 T cell engagers have also received accelerated approvals, their short half-lives require frequent and ongoing dosing. Emerging strategies to solve these challenges include in vivo engineering of circulating T cells, using viral vectors or polymeric/lipid nanoparticles functionalized with pan-T cell antibodies to deliver plasmid DNA or mRNA encoding CAR transgenes. While promising, the limited specificity of these approaches can lead to transfection of autoimmune and regulatory T cells, which can increase off-target toxicity, break self-tolerance and reduce treatment efficacy. This proposal seeks to develop Ag-presenting lipid nanoparticles (APNs) to deliver BCMA CAR mRNA to defined immune effector cell subsets for MM treatment. Therapy studies will be evaluated using MM mouse models grafted with both non-autologous (i.e., healthy donors) and autologous (i.e., patient derived) T cells. In both models, the impact of boosting BCMA CAR T cells using dendritic cell vaccines will be evaluated. The use of animal models is necessary for this project to emulate critical features such as systemic immune interactions, full tumor microenvironment heterogeneity, trafficking and persistence of CAR T cells, and whole-body pharmacokinetics and toxicity profiles. These can only be assessed in an in intact physiological system and murine models represent the least sentient system capable of accounting for these immune and biological responses. If successful, the proposal is expected to impact myeloma patients by significantly reducing manufacturing complexities, lowering costs, improving anti-cancer responses and broadening patient access to BCMA CAR T cell therapy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $705,899 )
2026	2026	GEORGIA TECH RESEARCH CORP	926 DALNEY ST NW	ATLANTA	GA	30318	FULTON	USA	Cancer Treatment Research	000	1	5/28/2026	NEW	$705,899
														Subtotal = $705,899

Grand Total All Awards = $705,899

Top

All Categories

About

Search

Reports

Data Submission

Award Information

In Vivo Engineering of Virus-Specific T Cells for CAR T Cell Therapy Against Multiple Myeloma

Award Number: R01CA304559

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2026

PERIOD OF PERFORMANCE END DATE: 05/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer